GLYCOMIMETICS INC (GLYC) Stock Price & Overview
NASDAQ:GLYC • US38000Q1022
The current stock price of GLYC is 0.157 USD. Today GLYC is down by -5.42%. In the past month the price decreased by -37.15%. In the past year, price decreased by -40.3%.
GLYC Key Statistics
- Market Cap
- 10.131M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.58
- Dividend Yield
- N/A
GLYC Stock Performance
GLYC Stock Chart
GLYC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GLYC. When comparing the yearly performance of all stocks, GLYC is a bad performer in the overall market: 93.78% of all stocks are doing better.
GLYC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLYC. While GLYC seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLYC Earnings
GLYC Forecast & Estimates
GLYC Groups
Sector & Classification
GLYC Financial Highlights
Over the last trailing twelve months GLYC reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 34.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -341.52% | ||
| ROE | -712.87% | ||
| Debt/Equity | 0 |
GLYC Ownership
GLYC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.51 | 406.874B | ||
| AMGN | AMGEN INC | 16.19 | 199.203B | ||
| GILD | GILEAD SCIENCES INC | 16.28 | 178.678B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.56 | 116.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.25 | 80.332B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.98 | 42.526B | ||
| INSM | INSMED INC | N/A | 30.205B | ||
| NTRA | NATERA INC | N/A | 28.081B | ||
| BIIB | BIOGEN INC | 11.5 | 27.132B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 20.958B | ||
| MRNA | MODERNA INC | N/A | 20.742B | ||
| EXAS | EXACT SCIENCES CORP | 340.51 | 19.757B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.5B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLYC
Company Profile
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The firm was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
Company Info
GLYCOMIMETICS INC
9708 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Rachel K. King
Employees: 4
Phone: 12402431201
GLYCOMIMETICS INC / GLYC FAQ
Can you describe the business of GLYCOMIMETICS INC?
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The firm was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
What is the current price of GLYC stock?
The current stock price of GLYC is 0.157 USD. The price decreased by -5.42% in the last trading session.
Does GLYCOMIMETICS INC pay dividends?
GLYC does not pay a dividend.
How is the ChartMill rating for GLYCOMIMETICS INC?
GLYC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is GLYCOMIMETICS INC (GLYC) stock traded?
GLYC stock is listed on the Nasdaq exchange.
Should I buy GLYC stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GLYC.
What is the market capitalization of GLYC stock?
GLYCOMIMETICS INC (GLYC) has a market capitalization of 10.13M USD. This makes GLYC a Nano Cap stock.